Alliqua buys Choice Therapeutics
LANGHORNE, Pa. – Alliqua, a provider of advanced wound care products, has acquired Choice Therapeutics for $4 million in stock and cash. The agreement, effective May 5, provides for an additional contingency payment of up to $5 million in stock or cash if stated revenue thresholds are reached over the next three years ending April 30, 2017. Alliqua has acquired Choice’s wound care portfolio, its technology platform, and its sales and marketing team. The portfolio includes a TheraBond Antimicrobial Barrier Systems technology that’s in wide use at key burn centers nationwide.